Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Cantor Fitzgerald Target 9$ CDN Cheers!!!

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Mar 06, 2023 12:51pm

164 Views

Post# 35321634

RE:Cantor Fitzgerald Target 9$ CDN Cheers!!!

It is always good to see a new/ additional analysis on- board.
the $9CDN price.
seems to be in the average of where things are.
all analysts have a buy rating or higher.
the jones & gabl3 report is very detailed.

A few points of consensus amongst them all.
1. opportunities are there, for Pela to get to market.
2. more news to come, ASCO & other dates.
3. the SP, will b3 rangebound until some form of Business development is announced.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages